| scholarly article | Q13442814 |
| P2093 | author name string | P Del Bianco | |
| J Pigozzo | |||
| V Chiarion-Sileni | |||
| L Corti | |||
| A Ruol | |||
| E Ancona | |||
| R Innocente | |||
| R Mazzarotto | |||
| C Boso | |||
| O Tomassi | |||
| P2860 | cites work | Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy | Q73794137 |
| Multimodality therapy for esophageal cancer | Q73804535 | ||
| Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study | Q73892657 | ||
| Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial | Q74463756 | ||
| Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group | Q77424043 | ||
| Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response | Q81394686 | ||
| Confidence limits for probability of response in multistage phase II clinical trials | Q93657901 | ||
| Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study. | Q33488335 | ||
| Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer | Q33503431 | ||
| The changing epidemiology of esophageal cancer | Q33776309 | ||
| Chemotherapy in esophageal cancer. | Q33776319 | ||
| An audit of the treatment of cancer of the oesophagus | Q34379065 | ||
| Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial | Q36616002 | ||
| Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy | Q36648089 | ||
| Surgical therapy of oesophageal carcinoma | Q37950431 | ||
| Estimates of the worldwide mortality from 25 cancers in 1990. | Q39358305 | ||
| Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival | Q39405901 | ||
| Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer | Q39436075 | ||
| A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report | Q40643414 | ||
| Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. | Q40667282 | ||
| Docetaxel: an active drug for squamous cell carcinoma of the head and neck | Q40669483 | ||
| Neoadjuvant therapy of esophageal cancer | Q40881796 | ||
| Carboplatin- and cisplatin-induced potentiation of moderate-dose radiation cytotoxicity in human lung cancer cell lines | Q41266661 | ||
| Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy v | Q43629491 | ||
| Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study | Q44159329 | ||
| Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer | Q44529248 | ||
| Phase II study of docetaxel and irinotecan in metastatic or recurrent esophageal cancer: a preliminary report | Q44625803 | ||
| Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study | Q44676959 | ||
| A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer | Q44902236 | ||
| Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. | Q45247420 | ||
| Optimal two-stage designs for phase II clinical trials | Q46412217 | ||
| Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the upper-thoracic and midthoracic esophagus. | Q53519360 | ||
| Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. | Q54027653 | ||
| Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma | Q57546312 | ||
| Histologic Tumor Type Is an Independent Prognostic Parameter in Esophageal Cancer: Lessons From More Than 1,000 Consecutive Resections at a Single Center in the Western World | Q58484706 | ||
| The calculation of received dose intensity | Q68588440 | ||
| Phase II study of cisplatin, 5-FU, and allopurinol in advanced esophageal cancer | Q68965550 | ||
| Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study | Q71975350 | ||
| A Controlled Trial of an Expansile Metal Stent for Palliation of Esophageal Obstruction Due to Inoperable Cancer | Q72099054 | ||
| Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus | Q72683495 | ||
| Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus | Q73181857 | ||
| Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer | Q73707393 | ||
| Multivariate analysis of treatment outcome in patients with esophageal carcinoma treated with definitive radiotherapy | Q73766818 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| cisplatin | Q412415 | ||
| carboplatin | Q415588 | ||
| docetaxel | Q420436 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 432-438 | |
| P577 | publication date | 2007-01-23 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer | |
| P478 | volume | 96 |
| Q37038184 | A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. |
| Q34204650 | Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study |
| Q33441947 | Cisplatin-based chemoradiotherapy with 5-fluorouracil or pemetrexed in patients with locally advanced, unresectable esophageal squamous cell carcinoma: A retrospective analysis |
| Q39157407 | Cocktail without hangover: in search for the optimal chemotherapy in the combined management of non-operable esophageal carcinomas. |
| Q35020568 | Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma. |
| Q83812136 | Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study |
| Q35659165 | External beam radiotherapy synergizes ¹⁸⁸Re-liposome against human esophageal cancer xenograft and modulates ¹⁸⁸Re-liposome pharmacokinetics |
| Q37250511 | Moscatilin induces apoptosis and mitotic catastrophe in human esophageal cancer cells |
| Q42731854 | Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer. |
| Q36104323 | Phase I Dose-Escalation Study of Docetaxel, Cisplatin, and 5-Fluorouracil Combination Chemotherapy in Patients With Advanced Esophageal Carcinoma |
| Q36940910 | Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma |
| Q37142445 | Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma |
| Q55658098 | Recent advancements in esophageal cancer treatment in Japan. |
| Q36999366 | Therapeutic and radiosensitizing effects of armillaridin on human esophageal cancer cells |
| Q37277133 | Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern |
| Q92690601 | Treatment and clinical outcome of clinical T4 esophageal cancer: A systematic review |
Search more.